Healthcare Continues to Drive Datwyler Earnings Growth

Swiss elastomer products manufacturer Datwyler has reported a 3.5% year-on-year increase in group sales to CHF582.7 million (€626 million) for the first six months, with earnings (EBIT) rising 9.9% to CHF75.7 million. The company’s healthcare division was the main driver of growth, with sales increasing to CHF242.8 million and division earnings rising sharply to CHF50.8 million, up 26% from the previous year. The healthcare segment’s margin improved to 20.9% from 16.9%, driven by the continued ramp-up of new customer projects and higher volumes in existing applications. Datwyler’s industrial division sales increased nearly 4% year-on-year to CHF342.4 million, but earnings declined 13.5% to CHF24.9 million due to weak demand and geopolitical uncertainty. The company expects the healthcare segment to remain the main growth driver, supported by higher-value products and increasing capacity utilization. Datwyler also began supplying components for a leading GLP-1 weight-loss medication and launched the industry’s first universal 20ml spray-coated plunger for large-volume injectable therapies.